Capacity to provide informed consent. (For patients under 17 years, participants must assent and informed consent provided by one parent or legal guardian).
Meet diagnostic criteria for Clinical High Risk of Psychosis (CHR).
For females of reproductive potential - not pregnant or nursing and willing to comply with contraceptive requirements.
You may not be if
Clinically significant medical disorder or laboratory test abnormality at Day 1.
History of or current condition which may prevent participant from complying with study procedures.
Past or current schizophrenia, other disorder with symptoms of psychosis, major cognitive disorder resulting from traumatic brain injury.
Received antipsychotic medication equivalent to a total lifetime haloperidol dose \>50 mg.
Current use of medications which could interfere with the study endpoints - to be assessed by the Investigator at screening.
Unable to abstain from nicotine (e.g. cigarettes, vape) for two hours before cognitive testing.
Unable to abstain from marijuana use on test day prior to test completion.
History of suicide attempt or behavior in previous 12 months, or risk of suicidal behavior during the study.
Clareo Health | A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
